Pfizer's BRAFTOVI combination shows positive results in Phase 3 trial for colorectal cancer

From Nasdaq: 2025-01-25 23:25:52

Pfizer Inc. announced positive results from the Phase 3 BREAKWATER trial for BRAFTOVI in combination with cetuximab and mFOLFOX6 in patients with metastatic colorectal cancer with a BRAF V600E mutation. The study showed an objective response rate of 61% with Pfizer’s combination regimen, doubling the odds of achieving an objective response compared to chemotherapy. The estimated median duration of response was 13.9 months with the BRAFTOVI combination. Overall survival data showed a promising trend in favor of BRAFTOVI plus cetuximab and mFOLFOX6. The BREAKWATER trial is ongoing for OS and PFS, with PFS results expected in 2025.



Read more at Nasdaq: PFE : BRAFTOVI Combination Shows Improved Response In Phase 3 Trial For Metastatic Colorectal Cancer